Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.7
3.0
Journals
JCM
Special Issues
Personalized Therapy and Clinical Outcomes for Congenital Heart Disease
share announcement

Personalized Therapy and Clinical Outcomes for Congenital Heart Disease

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Cardiology".

Deadline for manuscript submissions: 20 October 2025 | Viewed by 2466

Special Issue Editors

Dr. Giancarlo Scognamiglio

E-Mail Website
Guest Editor
Adult Congenital Heart Disease, Monaldi Hospital, Naples, Italy
Interests: non-invasive cardiac imaging; intraprocedural echocardiography; adult congenital heart disease; heart failure therapy; outcomes of congenital heart disease
Dr. Flavia Fusco

E-Mail
Guest Editor
Adult Congenital Heart Disease, Monaldi Hospital, Naples, Italy
Interests: non-invasive cardiac imaging; adult congenital heart disease; heart failure therapy; outcomes of congenital heart disease

Special Issue Information

Dear Colleagues,

Congenital heart disease (CHD) remains one of the most prevalent and challenging health conditions. Despite significant advances made in the diagnosis and treatment of CHD, there is still considerable variability in clinical outcomes among affected individuals. This diversity underscores the complex interplay of genetic, environmental, and developmental factors that contribute to the heterogeneous nature of CHD. Tailoring treatment strategies to the unique physiological characteristics of each patient holds the promise of optimizing clinical outcomes and improving long-term prognoses. From genomic profiling to advanced imaging techniques, the tools available for personalized medicine in CHD continue to evolve rapidly, offering unprecedented opportunities for precision diagnosis and targeted interventions. This Special Issue of the Journal of Clinical Medicine is dedicated to exploring the latest developments and breakthroughs in personalized therapy for CHD and their impacts on clinical outcomes. By bringing together cutting-edge research and clinical insights from experts in this field, we aim to shed light on the current state-of-the-art approaches, as well as the challenges and opportunities that lie ahead in the pursuit of personalized care for individuals with CHD. We invite original research articles and reviews that contribute to our understanding of personalized therapy for ACHD and its implications for clinical practice.

This Special Issue aims to:

  • Provide an overview of the unmet needs of the contemporary cohort of the aging CHD population, aiming to improve the outcomes and reduce the cardiac and extracardiac long-term complications.
  • Propose new strategies for the CHD cardiologists to care for the special needs of this extremely heterogenous population.
  • Promote a patient-centered care process, with the main aim of improving the perceived quality of life.
  • Describe the new knowledge gathered on the genetic and genomic profiling of CHD patients—from risk prediction to targeted therapies.
  • Illustrate the advances in imaging modalities for personalized diagnoses and treatment planning.
  • Propose a more extensive use of biomarkers in CHD for risk stratification and prognostication in the everyday clinical practice.
  • Provide insights into the novel, therapeutic, and preventive approches in CHD, with a special focus on pharmacogenomics and personalized drug therapies.
  • Propose new potential pathways for the management of specific lesions using a patient-tailored approach.
  • Describe the potential impact on the long-term outcomes of patient-tailored therapies applied to the special CHD population.

Dr. Giancarlo Scognamiglio
Dr. Flavia Fusco
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • personalized therapy
  • clinical outcome
  • heart failure therapy
  • anti-arrhythmic therapy
  • sudden death prevention
  • adult congenital heart failure
  • prognosis

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

10 pages, 498 KiB  
Article
Sacubitril/Valsartan and Dapagliflozin in Patients with a Failing Systemic Right Ventricle: Effects on the Arrhythmic Burden
by Giovanni Domenico Ciriello, Ippolita Altobelli, Flavia Fusco, Diego Colonna, Anna Correra, Giovanni Papaccioli, Emanuele Romeo, Giancarlo Scognamiglio and Berardo Sarubbi
J. Clin. Med. 2024, 13(24), 7659; https://doi.org/10.3390/jcm13247659 - 16 Dec 2024
Viewed by 930
Abstract
Background/Objectives: Angiotensin receptor neprilysin inhibitor (ARNI) and sodium-glucose co-transporter 2 inhibitors (SGLT2i) are essential medications in heart failure (HF) therapy, and their potential antiarrhythmic effects have been reported. Recently, ARNI and SGLT2i use for HF in adult congenital heart disease (ACHD) has [...] Read more.
Background/Objectives: Angiotensin receptor neprilysin inhibitor (ARNI) and sodium-glucose co-transporter 2 inhibitors (SGLT2i) are essential medications in heart failure (HF) therapy, and their potential antiarrhythmic effects have been reported. Recently, ARNI and SGLT2i use for HF in adult congenital heart disease (ACHD) has been studied. However, whether any beneficial effects may be achieved on the arrhythmic burden in the complex population of ACHD with a systemic right ventricle (sRV) is still to be determined. Methods: We retrospectively collected all significant arrhythmic events from a cohort of patients with a failing sRV attending our tertiary care center on optimal guideline-directed medical therapy (GDMT) with ARNI and/or SGLT2i. Results: A total of 46 patients (mean age 38.2 ± 10.7 years, 58% male) on sacubitril/valsartan were included. Twenty-three (50%) patients were also started on dapagliflozin. After a median follow-up of 36 [Q1–Q3: 34–38] months, arrhythmic events occurred globally in 13 (28%) patients. Survival analysis showed significant reduction of clinically relevant atrial and ventricular arrhythmia at follow-up (p = 0.027). Conclusions: Our findings suggest that GDMT including sacubitril/valsartan and dapagliflozin may also offer an antiarrhythmic effect in ACHD patients with a failing sRV, by reducing the incidence of arrhythmic events at follow-up. Full article
(This article belongs to the Special Issue Personalized Therapy and Clinical Outcomes for Congenital Heart Disease)
►▼ Show Figures

Figure 1

Review

Jump to: Research

13 pages, 16716 KiB  
Review
The Growing Role of Intracardiac Echo in Congenital Heart Disease Interventions
by Eihab Ghantous and Jamil A. Aboulhosn
J. Clin. Med. 2025, 14(7), 2414; https://doi.org/10.3390/jcm14072414 - 1 Apr 2025
Viewed by 376
Abstract
Advancements in congenital heart disease (CHD) care have significantly improved survival, leading to a growing population of adults with congenital heart disease (ACHDs). Many of these patients require ongoing interventions for residual defects, conduit or valve dysfunction, and arrhythmia management, often performed using [...] Read more.
Advancements in congenital heart disease (CHD) care have significantly improved survival, leading to a growing population of adults with congenital heart disease (ACHDs). Many of these patients require ongoing interventions for residual defects, conduit or valve dysfunction, and arrhythmia management, often performed using transcatheter techniques. Imaging plays a critical role in ensuring procedural success and safety. Intracardiac echocardiography (ICE) has emerged as an essential imaging modality in ACHD interventions. With continuous technological advancements, ICE offers several advantages over transesophageal echocardiography (TEE) and transthoracic echocardiography (TTE), including superior visualization, real-time guidance, and the ability to avoid general anesthesia. These benefits have made ICE the preferred imaging tool for many transcatheter procedures. This review explores the expanding role of ICE in ACHD interventions, highlighting its applications in structural and electrophysiological procedures. By enhancing procedural precision and reducing complications, ICE is transforming the management of ACHD patients, optimizing outcomes, and improving long-term care for this complex and growing population. Full article
(This article belongs to the Special Issue Personalized Therapy and Clinical Outcomes for Congenital Heart Disease)
►▼ Show Figures

Figure 1

21 pages, 11286 KiB  
Review
Multimodality Imaging Approach to Infective Endocarditis: Current Opinion in Patients with Congenital Heart Disease
by Nunzia Borrelli, Jolanda Sabatino, Alessia Gimelli, Martina Avesani, Valeria Pergola, Isabella Leo, Sara Moscatelli, Massimiliana Abbate, Raffaella Motta, Rosalba De Sarro, Jessica Ielapi, Federico Sicilia, Marco Alfonso Perrone, Pier Paolo Bassareo, Berardo Sarubbi and Giovanni Di Salvo
J. Clin. Med. 2025, 14(6), 1862; https://doi.org/10.3390/jcm14061862 - 10 Mar 2025
Viewed by 610
Abstract
Although advances in medical and surgical management have significantly improved clinical outcomes, infective endocarditis (IE) remains a significant threat to patients with congenital heart disease (CHD). The complexity of cardiac anatomy, the presence of prosthetic materials, and the emergence of novel pathogens pose [...] Read more.
Although advances in medical and surgical management have significantly improved clinical outcomes, infective endocarditis (IE) remains a significant threat to patients with congenital heart disease (CHD). The complexity of cardiac anatomy, the presence of prosthetic materials, and the emergence of novel pathogens pose unique diagnostic challenges in this specific population. However, the use of personalized imaging, integrating the strengths of each modality, has the potential to refine the diagnostic process, thereby optimizing diagnostic accuracy, guiding therapeutic decisions, and, ultimately, improving patient clinical outcomes. This review delves into the critical role of the multimodality imaging approach in the care of patients with IE and CHD, underscoring the importance of tailored and patient-centered management strategies in this vulnerable cohort. Full article
(This article belongs to the Special Issue Personalized Therapy and Clinical Outcomes for Congenital Heart Disease)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop